NY-ESO-1 antigen: A promising frontier in cancer immunotherapy

Abstract

	•Endogenous immune response: NY-ESO-1 exhibited high immunogenicity, activating endogenous dendritic cells, T cells and B cells.
	•NY-ESO-1-based cancer vaccines: NY-ESO-1 vaccines using protein/peptide, RNA/DNA, microbial vectors and artificial adjuvant vector cells have shown promise in enhancing immune responses against tumours.
	•NY-ESO-1-specific T-cell receptor-engineered cells: NY-ESO-1-targeted T cells, along with ongoing innovations in engineered natural killer cells and other cell therapies, have improved the efficacy of immunotherapy.

Keywords

cancer immunotherapy / cancer testis antigen / cancer vaccine / NY-ESO-1 / tumour microenvironment

References

[1] AbbottM, Ustoyev Y. Cancer and the immune system: the history and background of immunotherapy. Semin Oncol Nurs. 2019; 35: 150923.

[2] AhnR, CuiY, WhiteFM. Antigen discovery for the development of cancer immunotherapy. Semin Immunol. 2023; 66: 101733.

[3] ZhangY, ZhangZ. The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell Mol Immunol. 2020; 17: 807-821.

[4] HerlynD, Birebent B. Advances in cancer vaccine development. Ann Med. 1999; 31: 66-78.

[5] IlyasS, YangJC. Landscape of tumor antigens in T cell immunotherapy. J Immunol. 2015; 195: 5117-5122.

[6] AlmeidaLG, SakabeNJ, deOliveiraAR, et al. CTdatabase: a knowledge-base of high-throughput and curated data on cancer-testis antigens. Nucleic Acids Res. 2009; 37: D816-D819.

[7] GjerstorffMF, Andersen MH, DitzelHJ. Oncogenic cancer/testis antigens: prime candidates for immunotherapy. Oncotarget. 2015; 6: 15772-15787.

[8] ChenQ, Jackson H, ParenteP, et al. Immunodominant CD4+ responses identified in a patient vaccinated with full-length NY-ESO-1 formulated with ISCOMATRIX adjuvant. Proc Natl Acad Sci U S A. 2004; 101: 9363-9368.

[9] ChenYT, Scanlan MJ, SahinU, et al. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci U S A. 1997; 94: 1914-1918.

[10] JägerE, ChenYT, DrijfhoutJW, et al. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J Exp Med. 1998; 187: 265-270.

[11] PagottoA, Caballero OL, VolkmarN, et al. Centrosomal localisation of the cancer/testis (CT) antigens NY-ESO-1 and MAGE-C1 is regulated by proteasome activity in tumour cells. PLoS One. 2013; 8: e83212.

[12] SatieA-P, Rajpert-De Meyts E, SpagnoliGC, et al. The cancer–testis gene, NY-ESO-1, is expressed in normal fetal and adult testes and in spermatocytic seminomas and testicular carcinoma in situ. Lab Invest. 2002; 82: 775-780.

[13] GnjaticS, Nishikawa H, JungbluthAA, et al. NY-ESO-1: Review of an Immunogenic Tumor Antigen. Academic Press: 1-30. 10.1016/S0065-230X(06)95001-5

[14] SimpsonAJG, Caballero OL, JungbluthA, et al. Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer. 2006; 5: 615-625.

[15] EsfandiaryA, Ghafouri-Fard S. New York esophageal squamous cell carcinoma-1 and cancer immunotherapy. Immunotherapy. 2015; 7: 411-439.

[16] NicholaouT, EbertL, DavisID, et al. Directions in the immune targeting of cancer: lessons learned from the cancer–testis Ag NY-ESO-1. Immunol Cell Biol. 2006; 84: 303-317.

[17] JungbluthAA, ChenYT, StockertE, et al. Immunohistochemical analysis of NY-ESO-1 antigen expression in normal and malignant human tissues. Int J Cancer. 2001; 92: 856-860.

[18] CartronP-F, Blanquart C, HervouetE, et al. HDAC1-mSin3a-NCOR1, Dnmt3b-HDAC1-Egr1 and Dnmt1-PCNA-UHRF1-G9a regulate the NY-ESO1 gene expression. Mol Oncol. 2013; 7: 452-463.

[19] LiB, ZhuX, SunL, et al. Induction of a specific CD8+ T-cell response to cancer/testis antigens by demethylating pre-treatment against osteosarcoma. Oncotarget. 2014; 5: 10791-10802.

[20] GundaV, Frederick DT, BernasconiMJ, et al. A potential role for immunotherapy in thyroid cancer by enhancing NY-ESO-1. Cancer Antigen Expression Thyroid. 2014; 24: 1241-1250.

[21] NatsumeA, Wakabayashi T, TsujimuraK, et al. The DNA demethylating agent 5-aza-2′-deoxycytidine activates NY-ESO-1 antigenicity in orthotopic human glioma. Int J Cancer. 2008; 122: 2542-2553.

[22] HemmingerJA, Ewart Toland A, ScharschmidtTJ, et al. The cancer-testis antigen NY-ESO-1 is highly expressed in myxoid and round cell subset of liposarcomas. Mod Pathol. 2013; 26: 282-288.

[23] EndoM, de Graaff MA, IngramDR, et al. NY-ESO-1 (CTAG1B) expression in mesenchymal tumors. Mod Pathol. 2015; 28: 587-595.

[24] SölingA, SchurrP, BertholdF. Expression and clinical relevance of NY-ESO-1, MAGE-1 and MAGE-3 in neuroblastoma. Anticancer Res. 1999; 19: 2205-2209.

[25] BarrowC, Browning J, MacGregorD, et al. Tumor antigen expression in melanoma varies according to antigen and stage. Clin Cancer Res. 2006; 12: 764-771.

[26] RodolfoM, LukschR, StockertE, et al. Antigen-specific immunity in neuroblastoma patients: antibody and T-cell recognition of NY-ESO-1 tumor antigen. Cancer Res. 2003; 63: 6948-6955.

[27] OdunsiK, Jungbluth AA, StockertE, et al. NY-ESO-1 and LAGE-1 cancer–testis antigens are potential targets for immunotherapy in epithelial ovarian cancer. Cancer Res. 2003; 63: 6076-6083.

[28] JungbluthAA, Antonescu CR, BusamKJ, et al. Monophasic and biphasic synovial sarcomas abundantly express cancer/testis antigen ny-eso-1 but not mage-a1 or ct7. Int J Cancer. 2001; 94: 252-256.

[29] PollackSM, Jungbluth AA, HochBL, et al. NY-ESO-1 is a ubiquitous immunotherapeutic target antigen for patients with myxoid/round cell liposarcoma. Cancer. 2012; 118: 4564-4570.

[30] HeiSM, WeiHJ, ChenH, Wang JG. Pathological significance of NY-ESO-1 expression in the diagnosis of myxoid liposarcoma. Zhonghua Bing Li Xue Za Zhi. 2019; 48: 225-230. doi:10.3760/cma.j.issn.0529-5807.2019.03.011

[31] JoU, RohJ, SongMJ, et al. NY-ESO-1 as a diagnostic and prognostic marker for myxoid liposarcoma. Am J Transl Res. 2022; 14: 1268-1278.

[32] LaiJ-P, Robbins PF, RaffeldM, et al. NY-ESO-1 expression in synovial sarcoma and other mesenchymal tumors: significance for NY-ESO-1-based targeted therapy and differential diagnosis. Mod Pathol. 2012; 25: 854-858.

[33] LaiJ-P, Rosenberg AZ, MiettinenMM, LeeC-CR. NY-ESO-1 expression in sarcomas: a diagnostic marker and immunotherapy target. Oncoimmunology. 2012; 1: 1409-1410.

[34] SzenderJB, Papanicolau-Sengos A, EngKH, et al. NY-ESO-1 expression predicts an aggressive phenotype of ovarian cancer. Gynecol Oncol. 2017; 145: 420-425.

[35] RobbinsPF, MorganRA, FeldmanSA, et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol. 2011; 29: 917-924.

[36] LinetteGP, Stadtmauer EA, MausMV, et al. Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood. 2013; 122: 863-871.

[37] MorganRA, Chinnasamy N, Abate-DagaD, et al. Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J Immunother. 2013; 36: 133-151.

[38] CuriglianoG, VialeG, GhioniM, et al. Cancer-testis antigen expression in triple-negative breast cancer. Ann Oncol. 2011; 22: 98-103.

[39] StockertE, Jäger E, ChenYT, et al. A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. J Exp Med. 1998; 187: 1349-1354.

[40] JägerE, Stockert E, ZidianakisZ, et al. Humoral immune responses of cancer patients against “cancer–testis” antigen NY-ESO-1: correlation with clinical events. Int J Cancer. 1999; 84: 506-510.

[41] KurashigeT, Noguchi Y, SaikaT, et al. Ny-ESO-1 expression and immunogenicity associated with transitional cell carcinoma: correlation with tumor grade. Cancer Res. 2001; 61: 4671-4674.

[42] GatiA, LajmiN, DerouicheA, et al. NY-ESO-1 expression and immunogenicity in prostate cancer patients. Tunis Med. 2011; 89: 779-783.

[43] FujiwaraS, WadaH, KawadaJ, et al. NY-ESO-1 antibody as a novel tumour marker of gastric cancer. Br J Cancer. 2013; 108: 1119-1125.

[44] LuetkensT, KoboldS, CaoY, et al. Functional autoantibodies against SSX-2 and NY-ESO-1 in multiple myeloma patients after allogeneic stem cell transplantation. Cancer Immunol Immunother. 2014; 63: 1151-1162.

[45] OshimaY, Shimada H, YajimaS, et al. NY-ESO-1 autoantibody as a tumor-specific biomarker for esophageal cancer: screening in 1969 patients with various cancers. J Gastroenterol. 2016; 51: 30-34.

[46] JägerE, Jäger D, KarbachJ, et al. Identification of NY-ESO-1 epitopes presented by human histocompatibility antigen (HLA)-DRB4*0101-0103 and recognized by CD4(+) T lymphocytes of patients with NY-ESO-1-expressing melanoma. J Exp Med. 2000; 191: 625-630.

[47] ZarourHM, Storkus WJ, BrusicV, et al. NY-ESO-1 encodes DRB1*0401-restricted epitopes recognized by melanoma-reactive CD4+ T cells. Cancer Res. 2000; 60: 4946-4952.

[48] ZarourHM, Maillere B, BrusicV, et al. NY-ESO-1 119–143 is a promiscuous major histocompatibility complex class II T-helper epitope recognized by Th1-and Th2-type tumor-reactive CD4+ T cells. Cancer Res. 2002; 62: 213-218.

[49] ZengG, Touloukian CE, WangX, et al. Identification of CD4+ T cell epitopes from NY-ESO-1 presented by HLA-DR molecules. J Immunol. 2000; 165: 1153-1159.

[50] ZengG, WangX, RobbinsPF, et al. CD4(+) T cell recognition of MHC class II-restricted epitopes from NY-ESO-1 presented by a prevalent HLA DP4 allele: association with NY-ESO-1 antibody production. Proc Natl Acad Sci U S A. 2001; 98: 3964-3969.

[51] GnjaticS, Atanackovic D, JägerE, et al. Survey of naturally occurring CD4+ T cell responses against NY-ESO-1 in cancer patients: correlation with antibody responses. Proc Natl Acad Sci U S A. 2003; 100: 8862-8867.

[52] NeumannF, WagnerC, KubuschokB, et al. Identification of an antigenic peptide derived from the cancer-testis antigen NY-ESO-1 binding to a broad range of HLA-DR subtypes. Cancer Immunol Immunother. 2004; 53: 589-599.

[53] YuanJ, AdamowM, GinsbergBA, et al. Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab. Proc Natl Acad Sci U S A. 2011; 108: 16723-16728.

[54] ZengG, Aldridge ME, TianX, et al. Dendritic cell surface calreticulin is a receptor for NY-ESO-1: direct interactions between tumor-associated antigen and the innate immune system. J Immunol. 2006; 177: 3582-3589.

[55] LiuY, TianX, LeitnerWW, et al. Polymeric structure and host Toll-like receptor 4 dictate immunogenicity of NY-ESO-1 antigen in vivo. J Biol Chem. 2011; 286: 37077-37084.

[56] LiuY, ZengG. Cancer and innate immune system interactions: translational potentials for cancer immunotherapy. J Immunother. 2012; 35: 299-308.

[57] XuL, ZhengJ, NguyenDH, et al. Enhancing whole-tumor cell vaccination by engaging innate immune system through NY-ESO-1/dendritic cell interactions. J Immunother. 2013; 36: 412-422.

[58] AlsalloumA, Shevchenko JA, SennikovS. The melanoma-associated antigen family A (MAGE-A): a promising target for cancer immunotherapy? Cancers. 2023; 15:1779.

[59] DavisID, ChenW, JacksonH, et al. Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans. Proc Natl Acad Sci U S A. 2004; 101: 10697-10702.

[60] DiefenbachCSM, Gnjatic S, SabbatiniP, et al. Safety and immunogenicity study of NY-ESO-1b peptide and montanide ISA-51 vaccination of patients with epithelial ovarian cancer in high-risk first remission. Clin Cancer Res. 2008; 14: 2740-2748.

[61] IshikawaT, Kageyama S, MiyaharaY, et al. Safety and antibody immune response of CHP-NY-ESO-1 vaccine combined with poly-ICLC in advanced or recurrent esophageal cancer patients. Cancer Immunol Immunother. 2021; 70: 3081-3091.

[62] PavlickA, Blazquez AB, MeseckM, et al. Combined vaccination with NY-ESO-1 protein, poly-ICLC, and montanide improves humoral and cellular immune responses in patients with high-risk melanoma. Cancer Immunol Res. 2020; 8: 70-80.

[63] de Souza ApostólicoJ, LunardelliVAS, Coirada FC, et al. Adjuvants: classification, modus operandi, and licensing. J Immunol Res. 2016; 2016: 1459394.

[64] KarbachJ, Neumann A, AtmacaA, et al. Efficient in vivo priming by vaccination with recombinant NY-ESO-1 protein and CpG in antigen naive prostate cancer patients. Clin cancer Res. 2011; 17: 861-870.

[65] TakeokaT, NagaseH, KuroseK, et al. NY-ESO-1 protein cancer vaccine with poly-ICLC and OK-432: rapid and strong induction of NY-ESO-1-specific immune responses by poly-ICLC. J Immunother. 2017; 40: 140-147.

[66] LiM, ShiH, MuY, et al. Effective inhibition of melanoma tumorigenesis and growth via a new complex vaccine based on NY-ESO-1-alum-polysaccharide-HH2. Mol Cancer. 2014; 13: 179.

[67] IshiharaM, TonoY, MiyaharaY, et al. First-in-human phase I clinical trial of the NY-ESO-1 protein cancer vaccine with NOD2 and TLR9 stimulants in patients with NY-ESO-1-expressing refractory solid tumors. Cancer Immunol Immunother. 2020; 69: 663-675.

[68] KarbachJ, Gnjatic S, BenderA, et al. Tumor-reactive CD8+ T-cell responses after vaccination with NY-ESO-1 peptide, CpG 7909 and Montanide ISA-51: association with survival. Int J Cancer. 2010; 126: 909-918.

[69] ValmoriD, Souleimanian NE, ToselloV, et al. Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming. Proc Natl Acad Sci U S A. 2007; 104: 8947-8952.

[70] KageyamaS, WadaH, MuroK, et al. Dose-dependent effects of NY-ESO-1 protein vaccine complexed with cholesteryl pullulan (CHP-NY-ESO-1) on immune responses and survival benefits of esophageal cancer patients. J Transl Med. 2013; 11: 246.

[71] TsujiT, Sabbatini P, JungbluthAA, et al. Effect of Montanide and poly-ICLC adjuvant on human self/tumor antigen-specific CD4+ T cells in phase I overlapping long peptide vaccine trial. Cancer Immunol Res. 2013; 1: 340-350.

[72] SabbatiniP, TsujiT, FerranL, et al. Phase I trial of overlapping long peptides from a tumor self-antigen and poly-ICLC shows rapid induction of integrated immune response in ovarian cancer patients. Clin Cancer Res. 2012; 18: 6497-6508.

[73] DutoitV, TaubRN, PapadopoulosKP, et al. Multiepitope CD8(+) T cell response to a NY-ESO-1 peptide vaccine results in imprecise tumor targeting. J Clin Invest. 2002; 110: 1813-1822.

[74] BioleyG, Guillaume P, LuescherI, et al. Vaccination with a recombinant protein encoding the tumor-specific antigen NY-ESO-1 elicits an A2/157-165-specific CTL repertoire structurally distinct and of reduced tumor reactivity than that elicited by spontaneous immune responses to NY-ESO-1-expression. J Immunother. 2009; 32:161-168.

[75] Le GalF-A, AyyoubM, DutoitV, et al. Distinct structural TCR repertoires in naturally occurring versus vaccine-induced CD8+ T-cell responses to the tumor-specific antigen NY-ESO-1. J Immunother. 2005; 28: 252-257.

[76] DhodapkarMV, SznolM, ZhaoB, et al. Induction of antigen-specific immunity with a vaccine targeting NY-ESO-1 to the dendritic cell receptor DEC-205. Sci Transl Med. 2014; 6:232ra51.

[77] BhardwajN, Pavlick AC, ErnstoffMS, et al. A phase II randomized study of CDX-1401, a dendritic cell targeting NY-ESO-1 vaccine, in patients with malignant melanoma pre-treated with recombinant CDX-301, a recombinant human Flt3 ligand. J Clin Oncol. 2016; 34: 9589.

[78] KleinO, DavisID, McArthurGA, et al. Low-dose cyclophosphamide enhances antigen-specific CD4(+) T cell responses to NY-ESO-1/ISCOMATRIX^™ vaccine in patients with advanced melanoma. Cancer Immunol Immunother. 2015; 64: 507-518.

[79] AndersonKG, Stromnes IM, GreenbergPD. Obstacles posed by the tumor microenvironment to T cell activity: a case for synergistic therapies. Cancer Cell. 2017; 31: 311-325.

[80] RestifoNP, YingH, HwangL, Leitner WW. The promise of nucleic acid vaccines. Gene Ther. 2000; 7: 89-92.

[81] RoyS, SethiTK, TaylorD, et al. Breakthrough concepts in immune-oncology: cancer vaccines at the bedside. J Leukoc Biol. 2020; 108: 1455-1489.

[82] GnjaticS, Altorki NK, TangDN, et al. NY-ESO-1 DNA vaccine induces T-cell responses that are suppressed by regulatory T cells. Clin Cancer Res. 2009; 15: 2130-2139.

[83] PudneyVA, Metheringham RL, GunnB, et al. DNA vaccination with T-cell epitopes encoded within Ab molecules induces high-avidity anti-tumor CD8+ T cells. Eur J Immunol. 2010; 40: 899-910.

[84] XueW, Metheringham RL, BrentvilleVA, et al. SCIB2, an antibody DNA vaccine encoding NY-ESO-1 epitopes, induces potent antitumor immunity which is further enhanced by checkpoint blockade. Oncoimmunology. 2016; 5: e1169353.

[85] MyhrAI. DNA vaccines: regulatory considerations and safety aspects. Curr Issues Mol Biol. 2017; 22: 79-88.

[86] SahinU, OehmP, DerhovanessianE, et al. An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma. Nature. 2020; 585: 107-112.

[87] PapachristofilouA, Hipp MM, KlinkhardtU, et al. Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer. J Immunother cancer. 2019; 7: 38.

[88] ZhouM, TangY, XuW, et al. Bacteria-based immunotherapy for cancer: a systematic review of preclinical studies. Front Immunol. 2023; 14: 1140463.

[89] NishikawaH, SatoE, BrionesG, et al. In vivo antigen delivery by a Salmonella typhimurium type III secretion system for therapeutic cancer vaccines. J Clin Invest. 2006; 116: 1946-1954.

[90] NishikawaH, TsujiT, JägerE, et al. Induction of regulatory T cell-resistant helper CD4+ T cells by bacterial vector. Blood. 2008; 111: 1404-1412.

[91] CrittendenM, BahjatKS, LiR, et al. Phase I study of safety and immunogenicity of ADU-623, a live-attenuated listeria monocytogenes vaccine (ΔactA/ΔinlB) expressing EGFRVIII and NY-ESO-1, in patients with who grade III/IV astrocytomas. J Immunother Cancer. 2015; 3: P162.

[92] UraT, OkudaK, ShimadaM. Developments in viral vector-based vaccines. Vaccines. 2014; 2: 624-641.

[93] KaczmarekM, Poznańska J, FechnerF, et al. Cancer vaccine therapeutics: limitations and effectiveness—a literature review. Cells. 2023; 12:2159.

[94] MarshallJL, Hawkins MJ, TsangKY, et al. Phase I study in cancer patients of a replication-defective Avipox recombinant vaccine that expresses human carcinoembryonic antigen. J Clin Oncol. 1999; 17: 332.

[95] JägerE, Karbach J, GnjaticS, et al. Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients. Proc Natl Acad Sci U S A. 2006; 103: 14453-14458.

[96] OdunsiK, Matsuzaki J, KarbachJ, et al. Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY-ESO-1 antigen in ovarian cancer and melanoma patients. Proc Natl Acad Sci U S A. 2012; 109: 5797-5802.

[97] VogelTU, VisanL, LjuticB, et al. Preclinical qualification of a new multi-antigen candidate vaccine for metastatic melanoma. J Immunother. 2010; 33: 743-758.

[98] AlbershardtTC, Campbell DJ, ParsonsAJ, et al. LV305, a dendritic cell-targeting integration-deficient ZVex(TM)-based lentiviral vector encoding NY-ESO-1, induces potent anti-tumor immune response. Mol Ther Oncolytics. 2016; 3: 16010.

[99] PollackSM, LuH, GnjaticS, et al. First-in-human treatment with a dendritic cell-targeting lentiviral vector-expressing NY-ESO-1, LV305, induces deep, durable response in refractory metastatic synovial sarcoma patient. J Immunother. 2017; 40: 302-306.

[100] SomaiahN, ChawlaSP, BlockMS, et al. A phase 1b study evaluating the safety, tolerability, and immunogenicity of CMB305, a lentiviral-based prime-boost vaccine regimen, in patients with locally advanced, relapsed, or metastatic cancer expressing NY-ESO-1. Oncoimmunology. 2020; 9: 1847846.

[101] ChawlaSP, Van Tine BA, PollackSM, et al. Phase II randomized study of CMB305 and atezolizumab compared with atezolizumab alone in soft-tissue sarcomas expressing NY-ESO-1. J Clin Oncol. 2022; 40: 1291-1300.

[102] PaluckaK, Banchereau J. Dendritic-cell-based therapeutic cancer vaccines. Immunity. 2013; 39: 38-48.

[103] OsugiY, Vuckovic S, HartDNJ. Myeloid blood CD11c(+) dendritic cells and monocyte-derived dendritic cells differ in their ability to stimulate T lymphocytes. Blood. 2002; 100: 2858-2866.

[104] CollinM, BigleyV. Human dendritic cell subsets: an update. Immunology. 2018; 154: 3-20.

[105] WestdorpH, Creemers JHA, van OortIM, et al. Blood-derived dendritic cell vaccinations induce immune responses that correlate with clinical outcome in patients with chemo-naive castration-resistant prostate cancer. J Immunother cancer. 2019; 7: 302. doi:10.1186/s40425-019-0787-6

[106] FujiiS-I, Yamasaki S, HanadaK, et al. Cancer immunotherapy using artificial adjuvant vector cells to deliver NY-ESO-1 antigen to dendritic cells in situ. Cancer Sci. 2022; 113: 864-874.

[107] KeenanBP, JaffeeEM. Whole cell vaccines—past progress and future strategies. Semin Oncol. 2012; 39: 276-286.

[108] HunderNN, WallenH, CaoJ, et al. Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N Engl J Med. 2008; 358: 2698-2703.

[109] RobbinsPF, KassimSH, TranTLN, et al. A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response. Clin Cancer Res. 2015; 21: 1019-1027.

[110] KawaiA, Ishihara M, NakamuraT, et al. Safety and efficacy of NY-ESO-1 antigen-specific T-cell receptor gene-transduced T lymphocytes in patients with synovial sarcoma: a phase I/II clinical trial. Clin Cancer Res. 2023; 29: 5069-5078.

[111] KawaiA, Ishihara M, NakamuraT, et al. Results from phase I/II study of NY-ESO-1-specific TCR gene-transduced T cell therapy (TBI-1301, mipetresgene autoleucel) in patients with advanced synovial sarcoma. J Clin Oncol. 2023; 41: 11558.

[112] D’AngeloSP, Melchiori L, MerchantMS, et al. Antitumor activity associated with prolonged persistence of adoptively transferred NY-ESO-1 (c259)T cells in synovial sarcoma. Cancer Discov. 2018; 8: 944-957.

[113] JosephJ, Nathenson MJ, TrinhVA, et al. Guillain–Barre syndrome observed with adoptive transfer of lymphocytes genetically engineered with an NY-ESO-1 reactive T-cell receptor. J Immunother Cancer. 2019; 7: 296.

[114] RapoportAP, Stadtmauer EA, Binder-SchollGK, et al. NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma. Nat Med. 2015; 21: 914-921. doi:10.1038/nm.3910

[115] StadtmauerEA, FaitgTH, LowtherDE, et al. Long-term safety and activity of NY-ESO-1 SPEAR T cells after autologous stem cell transplant for myeloma. Blood Adv. 2019; 3: 2022-2034.

[116] FrankiwL, SinghA, PetersC, et al. Immunotherapy resistance driven by loss of NY-ESO-1 expression in response to transgenic adoptive cellular therapy with PD-1 blockade. J Immunother Cancer. 2023; 11: e006930.

[117] MaL, Hostetler A, MorganDM, et al. Vaccine-boosted CAR T crosstalk with host immunity to reject tumors with antigen heterogeneity. Cell. 2023; 186: 3148-3165.

[118] MoynihanKD, OpelCF, SzetoGL, et al. Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses. Nat Med. 2016; 22: 1402-1410.

[119] LiuH, Moynihan KD, ZhengY, et al. Structure-based programming of lymph-node targeting in molecular vaccines. Nature. 2014; 507: 519-522.

[120] TrevaskisNL, Kaminskas LM, PorterCJH. From sewer to saviour—targeting the lymphatic system to promote drug exposure and activity. Nat Rev Drug Discov. 2015; 14: 781-803.

[121] SteinbuckMP, Seenappa LM, JakubowskiA, et al. A lymph node-targeted Amphiphile vaccine induces potent cellular and humoral immunity to SARS-CoV-2. Sci Adv. 2021; 7: eabe5819.

[122] DrakesDJ, AbbasAM, ShieldsJ, et al. Lymph node-targeted vaccine boosting of TCR T-cell therapy enhances antitumor function and eradicates solid tumors. Cancer Immunol Res. 2024; 12: 214-231.

[123] IshiharaM, KitanoS, KageyamaS, et al. NY-ESO-1-specific redirected T cells with endogenous TCR knockdown mediate tumor response and cytokine release syndrome. J Immunother Cancer. 2022; 10: e003811.

[124] IshiharaM, Nishida Y, KitanoS, et al. A phase 1 trial of NY-ESO-1-specific TCR-engineered T-cell therapy combined with a lymph node-targeting nanoparticulate peptide vaccine for the treatment of advanced soft tissue sarcoma. Int J Cancer. 2023; 152: 2554-2566.

[125] HanahanD, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144: 646-674.

[126] SiegelPM, Massagué J. Cytostatic and apoptotic actions of TGF-beta in homeostasis and cancer. Nat Rev Cancer. 2003; 3: 807-821.

[127] TravisMA, Sheppard D. TGF-β activation and function in immunity. Annu Rev Immunol. 2014; 32: 51-82.

[128] ZhangQ, YangX, PinsM, et al. Adoptive transfer of tumor-reactive transforming growth factor-beta-insensitive CD8+ T cells: eradication of autologous mouse prostate cancer. Cancer Res. 2005; 65: 1761-1769.

[129] SunJ, Kavathas PB. Comparison of the roles of CD8 alpha and CD8 alpha beta in interaction with MHC class I. J Immunol. 1997; 159: 6077-6082.

[130] WooldridgeL, van den Berg HA, GlickM, et al. Interaction between the CD8 coreceptor and major histocompatibility complex class I stabilizes T cell receptor-antigen complexes at the cell surface. J Biol Chem. 2005; 280: 27491-27501.

[131] BendleGM, Linnemann C, BiesL, et al. Blockade of TGF-β signaling greatly enhances the efficacy of TCR gene therapy of cancer. J Immunol. 2013; 191: 3232-3239.

[132] PatelY, HarrisB, BedardM, et al. 370 The Epi-RTM technology produces a polyclonal TIL product (LYL845) with a greater expansion success rate across hot and cold tumors, improved product phenotype, and maintenance of TCR diversity. J Immunother Cancer. 2022; 10: A389.

[133] KrishnaS, LoweryFJ, CopelandAR, et al. Stem-like CD8 T cells mediate response of adoptive cell immunotherapy against human cancer. Science. 2020; 370: 1328-1334.

[134] MuraokaD, HaradaN, HayashiT, et al. Nanogel-based immunologically stealth vaccine targets macrophages in the medulla of lymph node and induces potent antitumor immunity. ACS Nano. 2014; 8: 9209-9218.

[135] CaligiuriMA, Velardi A, ScheinbergDA, BorrelloIM. Immunotherapeutic approaches for hematologic malignancies. Hematology. 2004; 2004: 337-353.

[136] LiuE, TongY, DottiG, et al. Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity. Leukemia. 2018; 32: 520-531.

[137] SaetersmoenML, HammerQ, ValamehrB, et al. Off-the-shelf cell therapy with induced pluripotent stem cell-derived natural killer cells. Semin Immunopathol. 2019; 41: 59-68.

[138] AnguilleS, SmitsEL, LionE, et al. Clinical use of dendritic cells for cancer therapy. Lancet Oncol. 2014; 15: e257-e267.

[139] WilgenhofS, Corthals J, HeirmanC, et al. Phase II study of autologous monocyte-derived mRNA electroporated dendritic cells (TriMixDC-MEL) plus ipilimumab in patients with pretreated advanced melanoma. J Clin Oncol. 2016; 34: 1330-1338.

[140] OdunsiK, Matsuzaki J, JamesSR, et al. Epigenetic potentiation of NY-ESO-1 vaccine therapy in human ovarian cancer. Cancer Immunol Res. 2014; 2: 37-49.

[141] ChouJ, VoongLN, MortalesCL, et al. Epigenetic modulation to enable antigen-specific T-cell therapy of colorectal cancer. J Immunother. 2012; 35: 131-141.

[142] FonteneauJF, BrilotF, MünzC, Gannagé M. The tumor antigen NY-ESO-1 mediates direct recognition of melanoma cells by CD4+ T cells after intercellular antigen transfer. J Immunol. 2016; 196: 64-71.

[143] TanMP, DoltonGM, GerryAB, et al. Human leucocyte antigen class I-redirected anti-tumour CD4+ T cells require a higher T cell receptor binding affinity for optimal activity than CD8+ T cells. Clin Exp Immunol. 2017; 187: 124-137.

[144] LiuX, XuY, XiongW, et al. Development of a TCR-like antibody and chimeric antigen receptor against NY-ESO-1/HLA-A2 for cancer immunotherapy. J Immunother Cancer. 2022; 10: e004035.

RIGHTS & PERMISSIONS

2024 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.